-
2023-509429-37-00
5
2022-10-03
Advanced or Metastatic Non-Small Cell Lung Cancer
-
2024-511209-49-00
6
2022-04-26
Patients with hormone receptor positive HER2 negative locally advanced
-
2024-516959-40-00
4
2021-08-17
This trial evaluates the efficacy and safety of Mirvetuximab soravtans
-
2024-514473-21-00
5
2021-06-21
Primary diffuse large B-cell lymphoma (DLBCL) of the central nervous s
-
2023-507961-24-00
5
2021-04-19
High-Risk HER2-Positive Breast Cancer
-
2024-514775-17-00
4
2021-02-10
Malignant B-cell lymphoma
-
2023-510390-33-00
5
2020-10-23
HER2-negative breast cancer patients with high relapse risk after
stan
-
2022-502478-18-00
4
2019-12-20
Acute Myeloid Leukemia (AML)
-
2023-503670-21-00
5
2019-08-28
Patients with newly diagnosed AML and intermediate- or adverse-risk ge
-
2023-507582-25-00
5
2019-08-02
Malignant Extracranial Germ Cell Tumours (MGCT)
-
2022-502832-37-00
5
2019-03-01
Acute myeloid leukemia
-
2023-503812-34-00
4
2019-02-13
Locally Advanced or Metastatic Disease in Solid Tumors
-
2023-509856-32-00
5
2018-07-15
acute lymphoblastic leukemia in children and adolescents
-
2024-513070-21-00
4
2018-02-15
Relapsed Acute Lymphoblastic Leukemia (ALL)
-
2024-515499-12-00
5
2017-10-02
Acute lymphoblastic leukemia
-
2023-505509-18-00
5
2017-07-12
mature aggressive B-cell lymphoma and leukemia in children and adolesc
-
2024-514841-12-00
5
2015-10-27
To determine whether the addition of palbociclib to adjuvant endocrine
-
2024-516240-26-00
5
2024-10-11
Influenza
-
2023-506425-12-00
5
2024-04-17
Uncontrolled and Resistant Hypertension
-
2022-501421-20-00
5
2024-04-09
Gout with hyperuricemia
-
2023-507358-34-00
4
2024-02-13
For the treatment of patients with chronic non-specific low back pain
-
2023-503688-41-00
5
2023-11-28
Primary Dysmenorrhea
-
2023-503763-42-00
5
2023-11-03
Healthy individuals or individuals with stable comorbidities which inc
-
2022-500897-32-00
5
2023-11-02
Chronic pain due to diabetic polyneuropathy